Virtus ETF Advisers LLC Gamida Cell Ltd. Transaction History

Virtus ETF Advisers LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $72,866 - $147,719	-33,121 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.85 - $6.44 $6,625 - $11,083	-1,721 Reduced 4.94%	33,121 $130,000
Q2 2021 Aug 10, 2021	BUY	$5.85 - $8.33 $10,530 - $14,994	1,800 Added 5.45%	34,842 $223,000
Q1 2021 May 17, 2021	BUY	$7.8 - $12.43 $4,578 - $7,296	587 Added 1.81%	33,042 $267,000
Q4 2020 Feb 12, 2021	BUY	$4.07 - $11.0 $132,091 - $357,005	32,455 New	32,455 $272,000

11.4M

235K

70.5K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.